Avalo Therapeutics
AVTX
13.58
-0.01
-0.07%
Avalo Therapeutics
US · AVTX
#3484 by market cap
13.58
-0.01
-0.07%
Live - 5344 symbols - heartbeat 293s ago
· 2026-10-08 08:02
Pre-market
14.14
+4.12%
After-hours
13.58
0.00%
- Market cap
- 728.30M
- P/E (TTM)i
- -3.08
- P/Bi
- 1.62
- EPSi
- -5.84
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on AVTX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 6.57, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -86.62% YoY
Margins
- Gross margin
- 100.00%
- Operating margin
- -123,601.69%
- Net margin
- -132,642.37%
Key ratios & quality
- Altman Z-Scorei
- 6.57
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.03M | 6.75M | 6.70M | 5.40M | 18.05M | 1.92M | 441.00K | 59.00K |
| Gross profit | 3.77M | 7.32M | 6.40M | 3.91M | 14.62M | 640.00K | 807.00K | 59.00K |
| Selling & admin expenses | 11.06M | 11.61M | 19.76M | 24.66M | 20.71M | 10.30M | 17.24M | 22.90M |
| Research & development | 5.79M | 11.76M | 32.19M | 59.84M | 31.31M | 13.78M | 24.44M | 50.08M |
| Operating profit | -14.90M | -17.39M | -47.29M | -82.13M | -37.44M | -23.44M | -40.87M | -72.93M |
| Pretax profit | -35.32M | -15.99M | -67.18M | -84.55M | -41.63M | -31.53M | -35.02M | -78.09M |
| Tax | -49.47K | 280.32K | -2.79M | -196.00K | 28.00K | 14.00K | 114.00K | 165.00K |
| Net profit | -40.05M | -16.07M | -63.50M | -84.38M | -41.66M | -31.54M | -35.13M | -78.26M |
| Basic EPS | -3.46K | -806 | -2.48K | -2.39K | -1.06K | -114 | -8 | -6 |
| Diluted EPS | -3,456.00 | -806.40 | -2,476.80 | -2,388.00 | -1,063.00 | -113.58 | -20.91 | -5.84 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | 0 | 59.00K | -- | -- |
| Gross profit | -- | -- | 0 | 59.00K | -- | -- |
| Selling & admin expenses | 5.55M | 5.24M | 5.58M | 6.53M | 6.85M | 8.10M |
| Research & development | 9.12M | 14.07M | 13.62M | 13.27M | 14.05M | 23.42M |
| Operating profit | -14.67M | -19.32M | -19.20M | -19.74M | -20.90M | -31.52M |
| Pretax profit | -13.14M | -20.75M | -30.61M | -13.59M | -19.62M | -36.34M |
| Tax | 8.00K | 16.00K | 11.00K | 130.00K | 12.00K | 18.00K |
| Net profit | -13.15M | -20.77M | -30.63M | -13.72M | -19.63M | -36.36M |
| Basic EPS | -1 | -2 | -2 | 0 | -1 | -1 |
| Diluted EPS | -1.25 | -1.92 | -2.19 | -0.37 | -0.98 | -0.83 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 21.93M | 17.72M | 26.01M | 61.85M | 16.42M | 8.40M | 138.89M | 105.29M |
| Cash & ST investments | 10.65M | 11.24M | 18.92M | 54.59M | 13.17M | 7.42M | 134.55M | 98.34M |
| Inventory | 317.92K | 21.33K | 3.00K | 38.00K | 20.00K | -- | -- | -- |
| Total assets | 70.25M | 36.11M | 43.76M | 80.21M | 33.37M | 20.99M | 150.73M | 116.46M |
| Total current liabilities | 26.22M | 12.16M | 15.23M | 19.89M | 22.11M | 4.62M | 6.96M | 12.94M |
| Short-term debt | -- | 155.82K | 426.00K | 485.00K | 6.46M | 537.00K | 568.00K | 392.00K |
| Long-term debt | -- | -- | -- | 32.83M | 13.49M | -- | -- | -- |
| Total liabilities | 49,342,973.00 | 15,113,405.00 | 19,193,000.00 | 57,132,000.00 | 44,282,000.00 | 13,689,000.00 | 17,700,000.00 | 33,409,000.00 |
| Total equity | 20.91M | 21.00M | 24.56M | 23.08M | -10.92M | 7.30M | 133.03M | 83.05M |
| Retained earnings | -98.22M | -114.29M | -177.79M | -262.17M | -303.82M | -335.13M | -370.26M | -448.52M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 126.94M | 115.19M | 113.85M | 105.29M | 88.83M | 407.93M |
| Cash & ST investments | 125.05M | 113.26M | 111.62M | 98.34M | 81.99M | 400.28M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 138.52M | 126.58M | 125.10M | 116.46M | 99.89M | 490.78M |
| Total current liabilities | 5.62M | 9.26M | 7.97M | 12.94M | 11.60M | 21.13M |
| Short-term debt | 526.00K | 482.00K | 438.00K | 392.00K | 328.00K | 242.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 15,908,000.00 | 22,009,000.00 | 33,553,000.00 | 33,409,000.00 | 31,565,000.00 | 42,123,000.00 |
| Total equity | 122.62M | 104.57M | 91.55M | 83.05M | 68.32M | 448.66M |
| Retained earnings | -383.41M | -404.18M | -434.80M | -448.52M | -468.15M | -504.51M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -3.13M | -19.13M | -40.54M | -70.89M | -26.75M | -30.68M | -49.06M | -51.46M |
| Depreciation & amortization | 4.55M | 3.88M | 1.84M | 1.66M | 166.00K | 158.00K | 169.00K | 344.00K |
| Free cash flow | -3.69M | -19.40M | -40.60M | -71.01M | -26.85M | -30.68M | -49.06M | -51.46M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 3.86M | 12.68M | 44.45M | 71.93M | -14.77M | 46.22M | 115.63M | 14.76M |
| Ending cash balance | 10.75M | 3.73M | 19.11M | 54.86M | 13.32M | 7.55M | 134.70M | 16.11M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -9.46M | -11.39M | -16.37M | -14.25M | -17.69M | -19.99M |
| Depreciation & amortization | 135.00K | 134.00K | 59.00K | 16.00K | 17.00K | 17.00K |
| Free cash flow | -9.46M | -11.39M | -16.37M | -14.25M | -17.69M | -19.99M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 14.37M | 392.00K | -- | -- |
| Ending cash balance | 125.24M | 42.52M | 27.26M | 16.11M | 25.32M | 85.61M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -171.07 | -76.72 | -253.06 | -347.91 | -684.77 | -- | -50.06 | -72.43 |
| ROA %i | -73.58 | -30.22 | -144.34 | -133.70 | -73.35 | -116.06 | -40.91 | -58.58 |
| ROIC %i | -104.90 | -76.72 | -248.61 | -145.12 | -127.33 | -- | -49.67 | -72.11 |
| 5-year avg ROE %i | -- | -- | -134.83 | -154.84 | -304.13 | -- | -- | -- |
| EBIT margin %i | -101.87 | -257.67 | -706.02 | -1,521.56 | -207.41 | -1,218.50 | -9,267.80 | -123,601.69 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.84 | 1.46 | 1.71 | 3.11 | 0.74 | 1.82 | 19.96 | 8.14 |
| Quick ratioi | 0.64 | 1.36 | 1.53 | 2.99 | 0.68 | 1.64 | 19.33 | 7.60 |
| Debt / assetsi | -- | 0.43 | 0.97 | 41.54 | 59.78 | 2.56 | 0.38 | 0.34 |
| LT debt / equityi | -- | -- | -- | 142.25 | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | 80.23 | -37.78 | -8.42 | 38.80 | -34.02 | -56.61 | -85.16 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 1,449.66 | -101.61 | -177.05 | -72.43 | -88.76 | -36.27 |
| ROA %i | 55.68 | -39.35 | -89.20 | -58.58 | -71.09 | -32.50 |
| ROIC %i | 1,248.71 | -100.05 | -175.15 | -72.11 | -88.24 | -36.21 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -11,408.39 | -13,640.59 | -34,632.29 | -123,601.69 | -134,164.41 | -154,847.46 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 22.61 | 12.44 | 14.28 | 8.14 | 7.66 | 19.31 |
| Quick ratioi | 22.27 | 12.23 | 14.00 | 7.60 | 7.07 | 18.94 |
| Debt / assetsi | 0.58 | 0.54 | 0.44 | 0.34 | 0.33 | 0.05 |
| LT debt / equityi | 0.22 | 0.19 | 0.13 | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Product revenue, net100.00%
Region
United States100.00%
Quote time 2026-10-08 08:02:58 · For reference only, not investment advice and not tailored to your situation.